HealthEquity (HQY) Stock Price, News & Analysis

Company Overview

HealthEquity, Inc. (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions. In 2020, the company expanded its suite of offerings through the acquisition of WageWorks, broadening its reach into commuter and lifestyle benefits. HealthEquity’s digital platform features online tools, mobile applications and customer support to simplify enrollment, claims processing and regulatory compliance for plan sponsors and participants.

HealthEquity is led by Chief Executive Officer Jon Kessler, supported by founder and Executive Chairman Stephen Nee. Under their stewardship, the company has focused on product innovation, strategic partnerships and operational efficiency to deliver scalable benefits solutions. HealthEquity continues to invest in technology enhancements and integrations aimed at empowering consumers to take greater control over their healthcare finances.

Key Stats

• Today's Range: $86.05 to $95.00
• 50-Day Range: $77.75 to $90.52
• 52-Week Range: $72.76 to $116.65
• Volume: 2.83 million shs
• Average Volume: 946,512 shs
• Market Capitalization: $7.36 billion
• P/E Ratio: 32.96
• Dividend Yield: N/A
• Price Target: $112.36
• Consensus Rating: Moderate Buy

HealthEquity Stock Analysis - MarketRank™

HealthEquity scored higher than 86% of companies evaluated by MarketBeat, and ranked 89th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

HealthEquity has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 1 strong buy rating, 12 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

HealthEquity has a consensus price target of $112.36, representing about 27.7% upside from its current price of $87.99.

Amount of Analyst Coverage

HealthEquity has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 15.63%

Earnings Growth

Earnings for HealthEquity are expected to grow by 15.63% in the coming year, from $3.84 to $4.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HealthEquity is 32.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.97.

Price to Earnings Ratio vs. Sector

The P/E ratio of HealthEquity is 32.96, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.63.

Price to Earnings Growth Ratio

HealthEquity has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

HealthEquity has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.45% of the float of HealthEquity has been sold short.

Short Interest Ratio / Days to Cover

HealthEquity has a short interest ratio ("days to cover") of 5.64.

Change versus previous month

Short interest in HealthEquity has recently decreased by 10.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HealthEquity does not currently pay a dividend.

Dividend Growth

HealthEquity does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.74

News Sentiment

HealthEquity has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for HealthEquity this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for HQY on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added HealthEquity to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HealthEquity insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.60% of the stock of HealthEquity is held by insiders.

Percentage Held by Institutions

99.55% of the stock of HealthEquity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/28/2026
• Today: 5/31/2026
• Fiscal Year End: 1/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:HQY
• CIK: 1428336
• Web: www.healthequity.com
• Phone: (801) 727-1000
• Fax: 801-727-1005
• Employees: 2,814
• Year Founded: 2002

Price Target and Rating

• Average Price Target for HealthEquity: $112.36
• High Price Target: $128.00
• Low Price Target: $89.00
• Potential Upside/Downside: +27.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.87
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.67
• Trailing P/E Ratio: 24.51
• Forward P/E Ratio: 22.91
• P/E Growth: 1.6
• Net Income: $215.20 million
• Net Margins: 17.25%
• Pretax Margin: 22.35%
• Return on Equity: 14.75%
• Return on Assets: 9.22%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 3.44
• Quick Ratio: 3.44

Sales & Book Value

• Annual Sales: $1.31 billion
• Price / Sales: 5.60
• Cash Flow: $5.28 per share
• Price / Cash Flow: 16.68
• Book Value: $24.66 per share
• Price / Book: 3.57

Miscellaneous

• Outstanding Shares: 83,600,000
• Free Float: 82,264,000
• Market Cap: $7.36 billion
• Optionable: Optionable
• Beta: 0.21